Morningstar Investment Management LLC Acquires 18,082 Shares of Prestige Consumer Healthcare Inc. $PBH

Morningstar Investment Management LLC grew its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 118.0% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 33,410 shares of the company’s stock after acquiring an additional 18,082 shares during the period. Morningstar Investment Management LLC’s holdings in Prestige Consumer Healthcare were worth $1,980,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in PBH. Lido Advisors LLC increased its holdings in shares of Prestige Consumer Healthcare by 5.4% during the 4th quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock worth $235,000 after acquiring an additional 192 shares during the last quarter. Cerity Partners LLC lifted its position in Prestige Consumer Healthcare by 5.9% during the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after acquiring an additional 218 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Prestige Consumer Healthcare by 110.1% during the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after acquiring an additional 219 shares during the period. Caitong International Asset Management Co. Ltd grew its position in shares of Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after purchasing an additional 236 shares during the last quarter. Finally, Diversify Advisory Services LLC grew its stake in shares of Prestige Consumer Healthcare by 4.6% in the third quarter. Diversify Advisory Services LLC now owns 5,837 shares of the company’s stock valued at $354,000 after acquiring an additional 256 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $49.67 on Friday. The stock has a market cap of $2.35 billion, a P/E ratio of 12.70, a P/E/G ratio of 1.60 and a beta of 0.35. The business’s fifty day moving average is $47.94 and its 200 day moving average is $56.91. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. Prestige Consumer Healthcare Inc. has a 12-month low of $42.62 and a 12-month high of $77.03.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). The business had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The business’s quarterly revenue was down 5.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PBH. Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Canaccord Genuity Group lowered their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Finally, Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $70.75.

Insider Activity

In related news, VP Jeffrey Zerillo sold 1,207 shares of the stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.50% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).